What happens when a relatively small informatics company is acquired by a very large healthcare corporation? Tom Wilkie looks at the case of Abbott Informatics and Starlims
Robert Roe looks at the software that can manage a product from the cradle to the grave - and beyond
Robert Roe finds that divergent safety regulations are forcing car manufacturers to turn to integrated simulation
In the first article in a series on future hardware for HPC, Robert Roe explains how OpenCL may make FPGAs an attractive option
At the intersection of big data, the cloud, and HPC, remote visualisation is anything but a remote prospect, as Tom Wilkie discovers
Work in the R&D laboratory starts with an idea and an experiment, not a sample. Sophia Ktori investigates how informatics packages are tailored to make life easier for scientists in the discovery laboratory
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
